Latest News - Valeant NJ

Friday, May 11, 2018

Valeant is Becoming Bausch Health Companies, Inc.

Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on the strong brand equity of the company’s businesses a…

Read the full story

Wednesday, April 04, 2018

GlobalData: Sun Pharma’s Ilumya To Face Strong Competition in the US market

It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from GlobalData, a leading data and analytics company.

 In March 2018 the US Food and Drug…

Read the full story

Friday, February 16, 2018

Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis

Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities …

Read the full story

Wednesday, February 14, 2018

FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment

The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved…

Read the full story

Friday, January 12, 2018

FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Form

The FDA has accepted  Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the firs…

Read the full story

Tuesday, November 14, 2017

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-y…

Read the full story

Thursday, November 02, 2017

FDA Accepts Ortho Dermatologic’s NDA for Novel Plaque Psoriasis Treatment, IDP-118

The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatme…

Read the full story

Friday, October 13, 2017

James P. Hartman Named New Vice President and General Manager at Solta Medical

James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a di…

Read the full story

Wednesday, October 04, 2017

Meet Thermage’s New FLX System

The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a…

Read the full story

Thursday, July 27, 2017

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Thursday, July 27, 2017

Valeant Launches Siliq Injection for Psoriasis

 Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York fro…

Read the full story

Tuesday, July 18, 2017

Valeant to Sell Obagi Medical Products Business for $190 M

Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acqui…

Read the full story

Wednesday, May 17, 2017

Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launch

Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman.  The team includes Michael McMyne, vice president of sales; Stac…

Read the full story

Monday, May 08, 2017

Valeant Appoints New Dermatology and Corporate Communications Leadership Members

Valeant Pharmaceuticals International, Inc. added new members to the dermatology leadership team -- Michael McMyne is the new Vice President of Sales and Stacey Williams is the new Vice President of M…

Read the full story

Friday, April 21, 2017

Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasis

Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per mon…

Read the full story
Load More